11 
unions, and private industry. At the request of the Chairman of the 
Committee, the Industrial Research Institute and the Pharmaceutical 
Manufacturers Association are surveying their member firms to determine 
the scope of the research efforts in the private sector. The Pharma- 
ceutical Manufacturers Association has adopted the NIH Guidelines 
for safe conduct of this research. 
In light of this review, the full Committee recommends that the 
following elements should be included in proposed legislation for the 
regulation of recombinant DNA research: 
( 1) Definitions : 
"Recombinant DNA molecules" should be defined in a manner consistent 
with the NIH Guidelines. 
Through an appropriate definition of the term "person," the legisla- 
tion should cover any individual, corporation, association, Federal, 
State, or local institution or agency, or other legal entity. 
"Secretary" should mean the Secretary of Health, Education, and Welfare. 
(2) General requirements : 
The legislation should bar any person from engaging in the production 
or use of recombinant DNA molecules in a State of the United States, in 
the District of Columbia, the Commonwealth of Puerto Rico, the Virgin 
Islands, American Samoa, Guam, the Trust Territory of the Pacific Islands, 
Wake Island, Outer Continental Shelf Lands as defined in the Outer Continen- 
tal Shelf Lands Act, Johnston Island, or the Canal Zone, unless (a) such 
production or use is permissible under standards promulgated by the 
Secretary, (b) such production or use is in compliance with any such 
[ 291 ] 
